UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000060129 |
|---|---|
| Receipt number | R000068769 |
| Scientific Title | Study on the Dose of Oligosaccharide That Affects the Gut Microbiota |
| Date of disclosure of the study information | 2025/12/19 |
| Last modified on | 2025/12/19 09:56:49 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Study on the Dose of Oligosaccharide That Affects the Gut Microbiota
Acronym
Study on the Dose of Oligosaccharide That Affects the Gut Microbiota
Scientific Title
Study on the Dose of Oligosaccharide That Affects the Gut Microbiota
Scientific Title:Acronym
Study on the Dose of Oligosaccharide That Affects the Gut Microbiota
Region
| Japan |
Condition
Condition
Healthy adults
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To examine the effect on gut microbiota by administration of oligosaccharide 1g for 2 weeks.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
Gut microbiota(relative abundance and total counts)
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Oral ingestion of oligosaccharide for 2 weeks
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1 Those who participated in the in-house monitoring program
2 Those whose workplace is the Meiji Innovation Center on the date of consent
3 Those who have received sufficient explanation about the purpose and content of this study,have the ability to consent,fully volunteered with voluntary intention,agreed to participate
Key exclusion criteria
1 Those who have participated in a study involving another intervention during the month prior to screening or who plan to participate in a study involving another intervention during the period between screening and the end of the intake period
2 Those who have a history of gastric or lower gastrointestinal tract surgery excluding hemorrhoids
3 Those who have a barium stomach X-ray, small or large intestine endoscopy, or bowel cleansing at a clinic or at home during the month prior to screening, or those who are scheduled to have these procedures during this study
4 Who have taken, ingested, or used drugs that may affect the study at least once a week during the month prior to screening, or who plan to take, ingest, or use these drugs at least once during the study
5 Those who plan to travel abroad, travel for more than one week, or go on a business trip during the period from one week prior to the intake period to the end of the intake period
6 Those who have food allergies
7 Those who are pregnant or breastfeeding
8. Subjects judged as unsuitable for the study by the principal investigator or research physician for other reasons
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | Hiroshi |
| Middle name | |
| Last name | Kano |
Organization
Meiji Holdings Co., Ltd.
Division name
Wellness Science Labs Research Team 1
Zip code
192-0919
Address
1-29-1 Nanakuni, Hachiouji, Tokyo, Japan
TEL
042-632-5838
hiroshi.kano@meiji.com
Public contact
Name of contact person
| 1st name | Chikaho |
| Middle name | |
| Last name | Sano |
Organization
Meiji Holdings Co., Ltd.
Division name
Wellness Science Labs Research Team 1
Zip code
192-0919
Address
1-29-1 Nanakuni, Hachiouji, Tokyo, Japan
TEL
042-632-5838
Homepage URL
chikaho.sano@meiji.com
Sponsor or person
Institute
Meiji Holdings Co., Ltd.
Institute
Department
Personal name
Funding Source
Organization
Meiji Holdings Co., Ltd.
Meiji Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Meiji Co., Ltd.
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Meiji Institutional Review Board
Address
1-29-1 Nanakuni, Hachiouji, Tokyo, Japan
Tel
042-632-5900
MEIJI.IRB@meiji.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2025 | Year | 12 | Month | 19 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2025 | Year | 12 | Month | 15 | Day |
Date of IRB
| 2025 | Year | 12 | Month | 11 | Day |
Anticipated trial start date
| 2025 | Year | 12 | Month | 22 | Day |
Last follow-up date
| 2026 | Year | 02 | Month | 22 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2025 | Year | 12 | Month | 19 | Day |
Last modified on
| 2025 | Year | 12 | Month | 19 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068769
